* This is the Professional Version. *
Bipolar disorders are characterized by episodes of mania and depression, which may alternate, although many patients have a predominance of one or the other. Exact cause is unknown, but heredity, changes in the level of brain neurotransmitters, and psychosocial factors may be involved. Diagnosis is based on history. Treatment consists of mood-stabilizing drugs, sometimes with psychotherapy.
Bipolar disorders usually begin in the teens, 20s, or 30s. Lifetime prevalence is about 4%. Rates of bipolar I disorder are about equal for men and women.
Bipolar disorders are classified as
Bipolar I disorder: Defined by the presence of at least one full-fledged (ie, disrupting normal social and occupational function) manic episode and usually depressive episodes
Bipolar II disorder: Defined by the presence of major depressive episodes with at least one hypomanic episode but no full-fledged manic episodes
Unspecified bipolar disorder: Disorders with clear bipolar features that do not meet the specific criteria for other bipolar disorders
In cyclothymic disorder (see Cyclothymic Disorder), patients have prolonged (> 2-yr) periods that include both hypomanic and depressive episodes; however, these episodes do not meet the specific criteria for a bipolar disorder.
Exact cause is unknown. Heredity plays a significant role. There is also evidence of dysregulation of serotonin and norepinephrine. Psychosocial factors may be involved. Stressful life events are often associated with initial development of symptoms and later exacerbations, although cause and effect have not been established.
Certain drugs can trigger exacerbations in some patients with bipolar disorder; these drugs include sympathomimetics (eg, cocaine, amphetamines), alcohol, and certain antidepressants (eg, tricyclics, MAOIs).
Bipolar disorder begins with an acute phase of symptoms, followed by a repeating course of remission and relapse. Remissions are often complete, but many patients have residual symptoms, and for some, the ability to function at work is severely impaired. Relapses are discrete episodes of more intense symptoms that are manic, depressive, hypomanic, or a mixture of depressive and manic features. Episodes last anywhere from a few weeks to 3 to 6 mo. Cycles—time from onset of one episode to that of the next—vary in length among patients. Some patients have infrequent episodes, perhaps only a few over a lifetime, whereas others have rapid-cycling forms (usually defined as ≥ 4 episodes/yr). Only a minority alternate back and forth between mania and depression with each cycle; in most, one or the other predominates to some extent.
Patients may attempt or commit suicide. Lifetime incidence of suicide in patients with bipolar disorder is estimated to be at least 15 times that of the general population.
A manic episode is defined as ≥ 1 wk of a persistently elevated, expansive, or irritable mood and persistently increased goal-directed activity or energy plus ≥ 3 additional symptoms:
Inflated self-esteem or grandiosity
Decreased need for sleep
Greater talkativeness than usual
Flight of ideas or racing of thoughts
Increased goal-directed activity
Excessive involvement in activities with high potential for painful consequences (eg, buying sprees, foolish business investments)
Manic patients may be inexhaustibly, excessively, and impulsively involved in various pleasurable, high-risk activities (eg, gambling, dangerous sports, promiscuous sexual activity) without insight into possible harm. Symptoms are so severe that they cannot function in their primary role (occupation, school, housekeeping). Unwise investments, spending sprees, and other personal choices may have irreparable consequences.
Patients in a manic episode may be exuberant and flamboyantly or colorfully dressed and often have an authoritative manner with a rapid, unstoppable flow of speech. Patients may make clang associations (new thoughts that are triggered by word sounds rather than meaning). Easily distracted, patients may constantly shift from one theme or endeavor to another. However, they tend to believe they are in their best mental state. Lack of insight and an increased capacity for activity often lead to intrusive behavior and can be a dangerous combination. Interpersonal friction results and may cause patients to feel that they are being unjustly treated or persecuted. As a result, patients may become a danger to themselves or to other people. Accelerated mental activity is experienced as racing thoughts by patients and is observed as flights of ideas by the physician.
Manic psychosis is a more extreme manifestation, with psychotic symptoms that may be difficult to distinguish from schizophrenia. Patients may have extreme grandiose or persecutory delusions (eg, of being Jesus or being pursued by the FBI), occasionally with hallucinations. Activity level increases markedly; patients may race about and scream, swear, or sing. Mood lability increases, often with increasing irritability. Full-blown delirium (delirious mania) may appear, with complete loss of coherent thinking and behavior.
A hypomanic episode is a less extreme variant of mania involving a distinct episode that lasts ≥ 4 days with behavior that is distinctly different from the patient’s usual nondepressed self and that includes ≥ 3 of the additional symptoms listed above under mania. During the hypomanic period, mood brightens, the need for sleep decreases, and psychomotor activity accelerates. For some patients, hypomanic periods are adaptive because they produce high energy, creativity, confidence, and supernormal social functioning. Many do not wish to leave the pleasurable, euphoric state. Some function quite well, and in most, functioning is not markedly impaired. However, in some patients, hypomania manifests as distractibility, irritability, and labile mood, which the patient and others find less attractive.
A depressive episode has features typical of major depression (see Depressive Disorders); the episode must include ≥ 5 of the following during the same 2-wk period, and one of them must be depressed mood or loss of interest or pleasure:
Depressed mood most of the day
Markedly diminished interest or pleasure in all or almost all activities for most of the day
Significant (> 5%) weight gain or loss or decreased or increased appetite
Insomnia (often sleep-maintenance insomnia) or hypersomnia
Psychomotor agitation or retardation observed by others (not self-reported)
Fatigue or loss of energy
Feelings of worthlessness or excessive or inappropriate guilt
Diminished ability to think or concentrate or indecisiveness
Recurrent thoughts of death or suicide, a suicide attempt, or specific plan for suicide
Psychotic features are more common in bipolar depression than in unipolar depression.
An episode of mania or hypomania is designated as having mixed features if ≥ 3 depressive symptoms are present for most days of the episode. This condition is often difficult to diagnose and may shade into a continuously cycling state; the prognosis is worse than that in a pure manic or hypomanic state.
Risk of suicide during mixed episodes is particularly high.
Diagnosis is based on identification of symptoms of mania or hypomania as described above, plus a history of remission and relapse. Symptoms must be severe enough to markedly impair social or occupational functioning or to require hospitalization to prevent harm to self or others. Some patients who present with depressive symptoms may have previously experienced hypomania or mania but do not report it unless they are specifically questioned. Skillful questioning may reveal morbid signs (eg, excesses in spending, impulsive sexual escapades, stimulant drug abuse), although such information is more likely to be provided by relatives. All patients must be asked gently but directly about suicidal ideation, plans, or activity.
Similar acute manic or hypomanic symptoms may result from stimulant abuse or physical disorders such as hyperthyroidism or pheochromocytoma. A review of substance use (especially of amphetamines and cocaine) and urine drug screening can help identify drug causes. However, because drug use may simply have triggered an episode in a patient with bipolar disorder, seeking evidence of symptoms (manic or depressive) not related to drug use is important. Patients with hyperthyroidism typically have other physical symptoms and signs (see Hyperthyroidism : Symptoms and Signs), but thyroid function testing (T4 and TSH levels) is a reasonable screen for new patients. Patients with pheochromocytoma are markedly hypertensive; if they are not, testing is not indicated.
Some patients with schizoaffective disorder (see Schizoaffective Disorder) have manic symptoms, but such patients rarely return to normal between episodes, and they, unlike most patients with mania, do not show interest in connecting with other people.
Patients with bipolar disorder may also have anxiety disorders (eg, social phobia, panic attacks, obsessive-compulsive disorders), possibly confusing the diagnosis.
Treatment usually has 3 phases:
Although most patients with hypomania can be treated as outpatients, severe mania or depression often requires inpatient management.
Drugs for bipolar disorder include
These drugs are used alone or in combination for all phases of treatment, although at different dosages.
Mood stabilizers consist of lithium and certain anticonvulsants, especially valproate, carbamazepine, and lamotrigine. Second-generation antipsychotics include aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone.
Specific antidepressants (eg, SSRIs) are sometimes added for severe depression, but their effectiveness is controversial; they are not recommended as sole therapy for depressive episodes.
Electroconvulsive therapy (ECT) is sometimes used for depression refractory to treatment and is also effective for mania. Phototherapy can be useful in treating seasonal bipolar I or bipolar II disorder (with autumn-winter depression and spring-summer hypomania). It is probably most useful as augmentative therapy.
Choice of drug can be difficult because all drugs have significant adverse effects, drug interactions are common, and no drug is universally effective. Selection should be based on what has previously been effective and well-tolerated in a given patient. If there is no prior experience (or it is unknown), choice is based on the patient’s medical history (vis-à-vis the adverse effects of the specific mood stabilizer) and the severity of symptoms.
For severe manic psychosis, in which immediate patient safety and management is compromised, urgent behavioral control usually requires a sedating 2nd-generation antipsychotic, sometimes supplemented initially with a benzodiazepine such as lorazepam or clonazepam 2 to 4 mg IM or po tid.
For less severe acute episodes in patients without contraindications (eg, renal disorders), lithium is a good first choice for both mania and depressive episodes. Because its onset is slow (4 to 10 days), patients with significant symptoms may also be given an anticonvulsant or a 2nd-generation antipsychotic. For those with depression, lamotrigine may be a good choice of anticonvulsant.
For bipolar depression, the best evidence suggests using quetiapine or lurasidone alone or the combination of fluoxetine and olanzapine.
Once remission is achieved, preventive treatment with mood stabilizers is indicated for all bipolar I patients. If episodes recur during maintenance treatment, clinicians should determine whether adherence is poor and, if so, whether nonadherence preceded or followed recurrence. Reasons for nonadherence should be explored to determine whether a change in mood stabilizer type or dosing would render treatment more acceptable.
As many as two thirds of patients with uncomplicated bipolar disorder respond to lithium, which attenuates bipolar mood swings but has no effect on normal mood. Whether lithium or another mood stabilizer is being used, breakthroughs are more likely in patients who have mixed states, rapid-cycling forms of bipolar disorder, comorbid anxiety, substance abuse, or a neurologic disorder.
Lithium carbonate is started at 300 mg po bid or tid and titrated, based on steady-state blood levels and tolerance, to a range of 0.8 to 1.2 mEq/L. Levels should be drawn after 5 days at a stable dose and 12 h after the last dose. Target drug levels for maintenance are lower, about 0.6 to 0.7 mEq/L. Higher maintenance levels are more protective against manic (but not depressive) episodes but have more adverse effects. Adolescents, whose glomerular function is excellent, need higher doses; elderly patients need lower doses.
Lithium can cause sedation and cognitive impairment directly or indirectly (by causing hypothyroidism) and often exacerbates acne and psoriasis. The most common acute, mild adverse effects are fine tremor, fasciculation, nausea, diarrhea, polyuria, polydipsia, and weight gain (partly attributed to drinking high-calorie beverages). These effects are usually transient and often respond to decreasing the dose slightly, dividing the dose (eg, tid), or using slow-release forms. Once dosage is established, the entire dose should be given after the evening meal. This dosing may improve adherence. A β-blocker (eg, atenolol 25 to 50 mg po once/day) can control severe tremor; however, some β-blockers (eg, propranolol) may worsen depression.
Acute lithium toxicity is manifested initially by gross tremor, increased deep tendon reflexes, persistent headache, vomiting, and confusion and may progress to stupor, seizures, and arrhythmias. Toxicity is more likely to occur in elderly patients, in patients with decreased creatinine clearance, and in those with Na loss (eg, due to fever, vomiting, diarrhea, or use of diuretics). Thiazide diuretics, ACE inhibitors, and NSAIDs other than aspirin may contribute to hyperlithemia. Lithium blood levels should be measured every 6 mo and whenever the dose is changed.
Long-term effects include hypothyroidism, particularly when there is a family history of hypothyroidism, and renal damage involving the distal tubule (mainly in patients with a history of renal parenchymal disease). Therefore, TSH levels should be monitored when lithium is started and annually thereafter if there is a family history of thyroid dysfunction or every other year for all other patients. Levels should also be measured whenever symptoms suggest thyroid dysfunction (including when mania recurs) because hypothyroidism may blunt the effect of mood stabilizers. BUN and creatinine should be measured at baseline, 2 or 3 times during the first 6 mo, and then once or twice a year.
Anticonvulsants that act as mood stabilizers, especially valproate and carbamazepine, are often used for acute mania and for mixed states (mania and depression). Lamotrigine is effective for mood-cycling and for depression. The precise mechanism of action for anticonvulsants in bipolar disorder is unknown but may involve γ-aminobutyric acid mechanisms and ultimately G-protein signaling systems. Their main advantages over lithium include a wider therapeutic margin and lack of renal toxicity.
For valproate , a loading dose of 20 mg/kg is given, then 250 to 500 mg po tid (extended-release formulation can be used); target blood levels are between 50 and 125 μg/mL. This approach does not result in more adverse effects than does gradual titration. Adverse effects include nausea, headache, sedation, dizziness, and weight gain; rare serious effects include hepatotoxicity and pancreatitis.
Carbamazepine should not be loaded; it should be started at 200 mg po bid and be increased gradually in 200-mg/day increments to target levels between 4 and 12 μg/mL (maximum, 800 mg bid). Adverse effects include nausea, dizziness, sedation, and unsteadiness. Very severe effects include aplastic anemia and agranulocytosis.
Lamotrigine is started at 25 mg po once/day for 2 wk, then 50 mg once/day for 2 wk, then 100 mg/day for 1 wk, and then can be increased by 50 mg each week as needed up to 200 mg once/day. Dosage is lower for patients taking valproate and higher for patients taking carbamazepine. Lamotrigine can cause rash and, rarely, the life-threatening Stevens-Johnson syndrome (see Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)), particularly if the dosage is increased more rapidly than recommended. While taking lamotrigine, patients should be encouraged to report any new rash, hives, fever, swollen glands, sores in the mouth and on the eyes, and swelling of the lips or tongue.
Acute manic psychosis is being increasingly managed with 2nd-generation antipsychotics, such as risperidone (usually 4 to 6 mg po once/day), olanzapine (usually 10 to 20 mg po once/day), quetiapine (200 to 400 mg po bid), ziprasidone (40 to 80 mg po bid), and aripiprazole (10 to 30 mg po once/day). In addition, evidence suggests that these drugs may enhance the effects of mood stabilizers after the acute phase.
Although any of these drugs may have extrapyramidal adverse effects and cause akathisia, risk is lower with more sedating drugs such as quetiapine and olanzapine. Less immediate adverse effects include substantial weight gain and development of the metabolic syndrome (including weight gain, excess abdominal fat, insulin resistance, and dyslipidemia); risk may be lower with the least sedating 2nd-generation antipsychotics, ziprasidone and aripiprazole. For extremely hyperactive psychotic patients with poor food and fluid intake, an antipsychotic given IM plus supportive care in addition to lithium or an anticonvulsant may be appropriate.
Lithium use during pregnancy has been associated with an increased risk of cardiovascular malformations (particularly Ebstein anomaly). However, the absolute risk of this particular malformation is quite low. Taking lithium during pregnancy appears to increase the relative risk of any congenital anomaly by about 2-fold, a risk similar to the 2- to 3-fold increased risk of congenital anomalies associated with use of carbamazepine or lamotrigine and is substantially lower than the risk associated with use of valproate. Valproate appears to increase risk of neural tube defects and autism spectrum disorders.
Extensive study of the use of 1st-generation antipsychotics and tricyclic antidepressants during early pregnancy has not revealed causes for concern. The same appears to be true of SSRIs, except for paroxetine. Data about the risks of 2nd-generation antipsychotics to the fetus are sparse as yet, even though these drugs are being more widely used for all phases of bipolar disorder.
Use of drugs (particularly lithium and SSRIs) before parturition may have carry-over effects on neonates.
Treatment decisions are complicated by the fact that with unplanned pregnancy, teratogenic effects may already have taken place by the time practitioners become aware of the issue. Consultation with a perinatal psychiatrist should be considered. In all cases, discussing the risks and benefits of treatment with patients is important.
Enlisting the support of loved ones is crucial to preventing major episodes. Group therapy is often recommended for patients and their partner; there, they learn about bipolar disorder, its social sequelae, and the central role of mood stabilizers in treatment. Individual psychotherapy may help patients better cope with problems of daily living and adjust to a new way of identifying themselves.
Patients, particularly those with bipolar II disorder, may not adhere to mood-stabilizer regimens because they believe that these drugs make them less alert and creative. The physician can explain that decreased creativity is relatively uncommon because mood stabilizers usually provide opportunity for a more even performance in interpersonal, scholastic, professional, and artistic pursuits.
Patients should be counseled to avoid stimulant drugs and alcohol, to minimize sleep deprivation, and to recognize early signs of relapse. If patients tend to be financially extravagant, finances should be turned over to a trusted family member. Patients with a tendency to sexual excesses should be given information about conjugal consequences (eg, divorce) and infectious risks of promiscuity, particularly AIDS.
Support groups (eg, the Depression and Bipolar Support Alliance [ DBSA ]) can help patients by providing a forum to share their common experiences and feelings.
Bipolar disorder is a cyclic condition that involves episodes of mania with or without depression (bipolar 1) or hypomania plus depression (bipolar 2).
Bipolar disorder markedly impairs the ability to function at work and to interact socially, and risk of suicide is significant; however, mild manic states (hypomania) are sometimes adaptive because they can produce high energy, creativity, confidence, and supernormal social functioning.
Length and frequency of cycles vary among patients; some patients have only a few over a lifetime, whereas others have ≥ 4 episodes/yr (rapid-cycling forms).
Only a few patients alternate back and forth between mania and depression during each cycle; in most cycles, one or the other predominates.
Diagnosis is based on clinical criteria, but stimulant abuse and physical disorders such as hyperthyroidism or pheochromocytoma must be ruled out by examination and testing.
Treatment depends on the manifestations and their severity but typically involves mood stabilizers (eg, lithium, valproate, carbamazepine, lamotrigine) and/or 2nd-generation antipsychotics (eg, aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone).
* This is the Professional Version. *